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Background: This study is to investigate the expression of progranulin (PGRN) in systemic lupus erythematosus
(SLE) patients and the effect of glucocorticoid (GC) treatment on its expression.
Methods: Thirty newly diagnosed severe SLE patients and 30 healthy subjects were enrolled in this study. The
serum levels of PGRN and the inflammatory factors of SLE were detected by ELISA and the mRNA expression of
these proteins were detected by real-time PCR.
Results: The serum levels of PGRN, IL-6, PR3, TNFR, TNF-α and anti-dsDNA antibody in SLE patients were increased
significantly compared with healthy controls (P < 0.05). The relative expression of PGRN mRNA was increased by
4.88-fold in pre-treatment SLE patients compared with controls (P < 0.05). After prednisone treatment, the serum
levels of PGRN decreased significantly, and the relative expression of PGRN mRNA was decreased by 1.34-fold
compared with the untreated controls (P < 0.01). Moreover, Serum concentration of PGRN was correlated with
serum levels of IL-6, TNF-α, TNFR and anti-dsDNA antibody in both pre-treatment and post-treatment SLE patients.
Conclusions: PGRN is up-regulated in the SLE patients and is correlated with pro-inflammatory cytokines and
anti-dsDNA antibody. Glucocorticoids can down-regulate the expression of PGRN in SLE patients.
Virtual slides: http://www.diagnosticpathology.diagnomx.eu/vs/1562484036905973
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Systemic lupus erythematosus (SLE) is a prototypic auto-
immune disease of unknown origin affecting major organs,
which mostly occurred in women of childbearing age. SLE
is primarily caused by high levels of autoantibodies and
immune complex deposition [1]. In SLE patients, disorder
cytokine production induces immunodeficiency and leads
to tissue inflammation and organ damage. The progranu-
lin protein (PGRN) is an autocrine growth factor with
multiple physiological and pathological functions. Tang W
et al. had found that PGRN can bind to TNF receptors and
is therapeutic against inflammatory arthritis in mice [2].
Therefore, PGRN is a potential target for the treatment of* Correspondence: qiufeng_sdu@163.com
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reproduction in any medium, provided the orautoimmune diseases. However, the expression changes of
PGRN in SLE patients remains unclear. Glucocorticoid
(GC) is an important drug for treatment of SLE. GC
inhibits the expression and function of many cytokines
though two pathways: the genomic pathway and the non-
genomic pathway [3,4]. However, whether GCs could exert
their function through affecting the expression of PGRN is
need to be studied.
In this study, we tested serum levels and mRNA levels
of PGRN, IL-6, proteinase3 (PR3), TNFR, TNF-α in the
peripheral blood mononuclear cells (PBMCs) of SLE pa-
tient and normal controls and dsDNA antibody to inves-
tigate the possible role of PGRN in SLE patients. The
possible effects of GCs on PGRN in SLE patients were
also determined.. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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Subjects
Thirty newly diagnosed SLE patients with SLEDAI ≥ 10
were recruited in the present study. All of the patients
met the American College of Rheumatology revised
criteria in 1997 for the classification of SLE [5]. None of
them had been treated with GCs and other immunosup-
pressive drugs prior to first collection of specimen. All
of them received prednisone 1 mg/kg/day for 21 consecu-
tive days. Peripheral blood samples were obtained again
3 weeks after prednisone administration. The control
group included 30 sex- and age-matched healthy volun-
teers (23 females and 7 males, age range 18–59 years,
median 30.1 years). All subjects signed informed consent
forms. Ethical approval for the research was obtained
from the Medical Ethical Committee of Qilu Hospital,
Shandong University.
Quantitative real-time polymerase chain reaction (RT -PCR)
PBMCs were separated by Red Blood Cell Lysis Buffer
(Pharmacia Diagnostics, Uppsala, Sweden), and the total
RNA was isolated by Trizol Reagent (Invitrogen, America)
according to the manufacturer’s instructions. RNA concen-
tration was determined using the Eppendorf Biophotometer
(Brinkmann Instruments, Westbury, NY, USA) and nor-
malized to 1 ug/ml for reverse transcription. The cDNA
was reverse-transcribed using the ReverTra Ace qPCR
RT Kit (Toyobo, Osaka, Japan). Real-time quantitative
PCR was performed by Light Cycler TaqMan Master
kit (Toyobo, Osaka, Japan) according to manufacturer’s
instruction on a Bio-rad IQ5 detection systems (Bio-rad,
CA, USA). The primers (Huada, Shanghai, China) used
for RT-PCR were shown in Table 1.
The following florescent real-time quantitative RT-PCR
by using SYBR Green (Toyobo, Osaka, Japan) conditions
were used: 95°C for 10 s, followed by 30 cycles of 95°C for
5 s and 60°C for 41 s. Each experiment were performed in
triplicate. The PCR products were separated in an agarose
gel to confirm the expected size. A melting-curve analysis
was also performed to ensure specificity of the products.
Relative expression of cytokine mRNAs was determined
by comparative Ct method (using arithmetic formulae) by
the relative expression software tool (Bio-rad, CA, USA),
and the relative expression of the PGRN was calculatedTable 1 Primers used in this study
Gene Forward primers (5′-3′) Reverse primers (5′-3′)
PGRN gatcctgcgagaaggaagtg ggccagtaatgcaggct
IL-6 aggagacttgcctggtgaaa gtactgggaatcggtacg
PR3 ccatgcggcatagctataatt gacctttattggcgtacttc
TNFR accaagtgccacaaaggaac gcggtaccatattaaccgg
GAPDH cagaacatcatccctgcctctac ggcattccggtcgtgggcusing the ΔΔCT method. Expression of mRNAs was nor-
malized to the expression of GAPDH gene.
ELISA
Five millilitres of heparinized venous peripheral blood
and five millilitres coagulation blood were collected from
each patient and control subjects before and after the
administration of prednisone. The blood was centrifuged
and the serum specimens were stored at −80°C. Serum
levels of PGRN, IL-6, PR3 and TNFR were measured
using a commercial ELISA assay kit (Yonghui, Beijing,
China) according to the manufacturer’s instruction.
Statistical analysis
Statistical analysis was performed using SPSS17.0. Data
were presented as median ± IQR. All the data were ana-
lyzed with the non-parameter test. The comparisons
among pre-treatment, post-treatment and control group
were performed by independent sample nonparametric test.
The correlations between PGRN and other cytokines or
anti-dsDNA antibody were assessed by Spearman rank cor-
relation. P < 0.05 was considered as statistically significant.
Results
Clinical characteristics
The clinic-pathological characteristics of the 30 patients
enrolled in this study were first analyzed. Among the pa-
tients, 23 were females and 7 were males, with ages ranged
from 12 to 52 years old (28.4 ± 9.3). The course of disease
from the presence of symptoms to the enrollment varied
from 1 to 37 months (12.6 ± 10.1). The systemic lupus
erythematosus disease activity index (SLEDAI) scores
ranged from 10 to 23 (15.1 ± 3.8) of pre-treatment and 6
to 22 (12.2 ± 4.0) of the post-treatment.
PGRN level was increased in the serum of SLE patients
To investigate the inflammatory effect of SLE, serum
levels of inflammatory cytokines, cytokine receptors as
well as dsDNAa antibody were detected by ELISA. The
levels of PGRN, IL-6, TNFR, TNF-α, PR3 and dsDNA
antibody in SLE patients (both pre-treatment and post-
treatment) with SLEDAI ≥ 10 were up-regulated signi-
ficantly compared with that of the normal controls
(p < 0.05, Table 2). Therefore, the level of PGRN was
changed in SLE patients compared with normal controls.
PGRN mRNA levels were increased in SLE patients
Next, changes in the PGRN mRNA level were determined
by real-time PCR. Using the IQ5 software, the data are
presented as the fold change in gene expression normal-
ized to GAPDH. The relative expression of PGRN mRNA
was increased by 4.88-fold in pre-treatment SLE patients
compared to normal controls (P < 0.01) (Figure 1).
Table 2 Comparison of serum levels of PGRN and other cytokines
Group n PGRN
(pg/l)
IL-6
(pg/ml)
PR3
(ng/ml)
TNFR
(ng/l)
TNFα
(ng/l)
Anti-dsDNA antibodies
(mg/l)
Pre-treatment 30 17.82 ± 5.18#& 1.56 ± 1.18#& 49.33 ± 18.85# 17.50 ± 10.33#& 89.59 ± 20.27#& 208.19 ± 194.24#&
Post-treatment 30 13.64 ± 4.51* 0.97 ± 0.37* 48.25 ± 10.89* 10.61 ± 3.70* 54.31 ± 17.17* 137.02 ± 80.71*
Control 30 11.09 ± 1.62 0.70 ± 0.05 38.32 ± 3.55 9.76 ± 1.06 37.46 ± 11.63 23.24 ± 20.23
Note: #, p < 0.05, compared with the normal controls.
&, p < 0.05, compared with the post-treatment group.
*, p < 0.05, compared with the normal controls.
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and inflammatory factors in the SLE patients
Prednisone was reported to decrease the level of IL-6
and TNF-α previously, so we investigated the effect of
prednisone on PGRN expression in SLE patients. After
treatment, there were significant downregulation in the
serum levels of PGRN (P = 0.02), IL-6 (P = 0.022), TNFR
(P = 0.003), TNF-α (P = 0.001) and anti-dsDNA antibody
(P = 0.038). However, the serum level of PR3 didn’t de-
creased after treatment (P = 0.549, Table 2).
Relative expression of PGRN mRNA was decreased
by 1.34-fold in post-treatment SLE patients compared
with pre-treatment ones (P < 0.05). Statistically signifi
cant downregulation of IL-6 (P < 0.05), PR3 (P < 0.05), and
TNFR (< 0.05) mRNA expressions was also detected in
post-treatment SLE patients compared with pre-treatment
SLE patients.
Correlations of PGRN with inflammatory factors in SLE
patients
To examine the relationship between serum PGRN level
and serum level of SLE-related inflammatory factors, cor-
relation between PGRN and other factors was analyzed by
Spearman rank correlation in SLE patients before and
after prednisone treatment. Results showed that the serum
concentration of PGRN was correlated with the levels
of IL-6 (r = 0.790, P < 0.01), TNFR (r = 0.559, P = 0.01),Figure 1 Quantitative RT-PCR analysis of PGRN mRNA levels. PBMCs w
Uppsala, Sweden), and total RNA was isolated by Trizol Reagent (Invitrogen
was run in triplicate. Expression of mRNAs was normalized to the expressioTNF-α (r = 0.438, P = 0.015) and anti-dsDNA antibody
(r = 0.906, P < 0.01) in the serum of pre-treatment SLE pa-
tients (Figure 2). After treatment of prednisone for 3 weeks,
serum concentrations of PGRN in the patients were
correlated with IL-6 (r = 0.836, P < 0.01), PR3 (r = 0.396,
P = 0.031), TNFR (r = 0.533, p = 0.02), TNF-α (r = 0.378,
P = 0.039) and anti-dsDNA antibody (r = 0.712, P < 0.01) in
post-treatment SLE patients (Figure 3). No correlation was
found between PGRN and PR3 in pre-treatment SLE
patients (r = 0.298, P = 0.110, data not shown).
Discussion
SLE is an autoimmune disease characterized by multiple
autoantibodies against self-directed antigens and multi-
systemic involvement. PGRN is an autocrine growth factor
contains seven and a half repeats of a cysteine-rich motif
in the order P–G–F–B–A–C–D–E, in which G–E are full
repeats and P is the half-motif [6]. PGRN is mainly
expressed in epithelial cells, immune cells, neurons [7],
and chondrocytes [8]. Moreover, high levels of PGRN
expression are found in a variety of human cancers [7].
Several studies have revealed that PGRN plays an import-
ant role in many pathological processes, including early
embryonic development, wound healing and inflammation
[8-13]. PGRN also functions as a regulator of cartilage
development and degradation [13], and PGRN exhibites
higher affinity for TNF receptors (TNFR), especiallyere separated by Red Blood Cell Lysis Buffer (Pharmacia Diagnostics,
, America) according to the manufacturer’s instructions. Each sample
n of GAPDH gene.
Figure 2 Spearman rank correlation analysis of PGRN and inflammatory factor in SLE patients before prednisone treatment. PGRN was
correlated with the levels of IL-6 (r = 0.790, P < 0.01), TNFR (r = 0.559, P = 0.01), TNF-α (r = 0.438, P = 0.015) and anti-dsDNA antibody (r = 0.906,
P < 0.01) in the serum of pre-treatment SLE patients. (A) Pre-treatment, IL-6 vs PGRN; (B) Pre-treament, TNFR vs PGRN; (C) Pre-treament, TNF-α vs
PGRN; (D) Pre-treament, dsDNA vs PGRN.
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the level of PGRN and TNFR was also increased in SLE
patients. PGRN acts as a powerful antagonist of TNF-α
signaling and disturbs the binding of TNF-α and TNFR
[2]. Previous researches showed that PGRN convectively
suppressed TNF-α-mediated activation of neutrophil
granulocyte [12] and degradation of chondrocyte [8].
In summary, PGRN, which binds directly to TNFR, is
involved in many physiological and pathological func-
tions. It also plays a critical role in the pathogenesis of
inflammatory arthritis in mice. Up-regulation of PGRN
has been reported in hemotherapy-induced amenorrhea
(CIA) [12]. Our present study showed that the level of
PGRN in peripheral blood was upregulated in both pre-
and post-treatment SLE patients compared to healthy
controls, which is in accordance with the above reports.
TNF shows different physiologic and pathogenic effects
in autoimmune diseases [14]. TNF has both immuno-suppressive and pro-inflammatory effects in SLE patient.
TNF is highly over expressed in both sera and renal tissue
of the lupus mice and the levels of TNF is correlated with
the degree of inflammatory organ disease. As the antagon-
ist of TNF-α, PGRN was over-expression in SLE sufferer.
So we think that PGRN is also a pathogenic factor of SLE.
Besides, active SLE patients have higher PGRN serum
levels compared with that treated with prednisone, which
lead us to speculate that PGRN expression is correlated
with disease activity.
Serine proteases can digest PGRN into individual
granulin units, which are actually pro-inflammatory and
can neutralize the anti-inflammatory effects of intact
PGRN [11,12]. Both neutrophil elastase and PR3 digest
PGRN to liberate granulin units [11,12]. In our study,
we also found that the level of PR3 is higher in SLE pa-
tients both before and after prednisone treatment.
Therefore the increases of PGRN detected in serum
Figure 3 Spearman rank correlation analysis of PGRN and inflammatory factor in SLE patients after prednisone treatment. PGRN was
correlated with IL-6 (r = 0.836, P < 0.01), PR3 (r = 0.396, P = 0.031), TNFR (r = 0.533, p = 0.02), TNF-α (r = 0.378, P = 0.039) and anti-dsDNA antibody
(r = 0.712, P < 0.01) in post-treatment SLE patients. (A) Post-treatment, IL-6 vs PGRN; (B) Post-treament, TNFR vs PGRN; (C) Post-treament, TNF-α vs
PGRN; (D) Post-treament, dsDNA vs PGRN.
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units. PGRN may function as a pro-inflammatory factor.
Further studies are needed to investigate the form of
PGRN in the serum of SLE patients. In post- treatment
SLE group, PGRN expression was lower than that in
pre-treatment group, but the level of PR3 showed no
change. Therefore, we suppose that PGRN could be used
as a molecular marker of SLE.
In the pre-treatment group, both IL-6 and ds-DNA
are higher than the post-treatment group and control
group. They are both correlated of linear with the levels
of PGRN (P < 0.05). IL-6 has been identified as an
important factor in the pathogenesis of SLE [15]. The
biological activities of IL-6 were diverse, inducing diffe-
rentiation of B cells in plasma cells and production of
IgG [16]. IL-6-deficient Mrl/lpr mice show a delayed on-
set of lupus nephritis and prolonged survival [17].Murine lupus models indicate the involvement of IL-6
in B-cell hyperactivation and the onset of SLE [18,19].
The upregulation of IL-6 levels we observed was in ac-
cordance with the above reports. IL-6 is also associated
with lupus nephritis and joint damage [20-22]. As IL-6
exerts both systemic and local effects, IL-6 targeting
therapy has been proved to be effecient in inflammatory
autoimmune diseases [23]. It has been shown that
patients with active SLE have increased serum level of
IL-6, which was correlated with disease activity or anti-
dsDNA levels [20,21]. Therefore, we analyzed the rela-
tionship between IL-6 and PGRN levels and showed that
they are correlated. Development of SLE is a very com-
plex process. Therefore, we need more objective infor-
mation to assess the disease activity in order to better
guide clinical diagnosis. PGRN will be a very useful
factor for the diagnosis of SLE. Therefore, PGRN was of
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ment of SLE severity.
GCs are powerful anti-inflammatory and immunosup-
pressive agents. They are widely used in systemic auto-
immune diseases, such as SLE, dermatomyositis and other
systemic diseases [24]. GCs exert their anti-inflammatory
and immunosuppressive roles by two different mecha-
nisms: the genomic pathway and the non-genomic path-
way [4]. The interaction of GCs and GC receptor (GR)
complex modulates gene expression to inhibit the transfer
of leucocyte to inflammation site and damage the function
of leucocyte, fibroblast and endothelial cells [3]. GCs
reduce the synthesis of pro-inflammatory cytokines, such
as IL-2, IL-6, TNF-α and prostaglandins (PGs) [24,25]. In
SLE patients, disorder cytokine production induces im-
munodeficiency and leads to tissue inflammation and organ
damage, such as diffuse proliferative lupus nephritis [26].
PR3 is involved in the development of a variety of auto-
immune diseases, such as Wegener’s granulomatosis [27].
Our present study showed that the levels of PGRN, IL-6,
TNFR, TNF-α and anti-dsDNA decreased after adminis-
tration of large doses of prednisone 1 mg/kg/day for four-
teen twenty-one consecutive days, and this was consistent
with the above reports. In a word, the present study dem-
onstrated that PGRN is up-regulated in both active and
GC-treated SLE patients. PGRN was concerned to be
correlated with the disease activity of SLE. Academic stu-
dies still needed to understand the precise mechanisms of
PGRN in regulating SLE. Since TNFR signaling is in-
volved SLE processes, antagonists of the TNF/TNFR
pathway may lead to a new therapeutics for this disease.
PGRN may be used as a diagnostic marker of systemic
lupus erythematosus.
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